As A Representative, Pompeo Signed Onto Sen. Cruz’s Letter To The FDA Criticizing Loosening Of Standards On Mifepristone. According to a press release from Sen. Cruz, “U.S. Sen. Ted Cruz (R-Texas) on Monday joined 74 members of Congress in sending a bicameral letter to Food and Drug Administration (FDA) Commissioner Robert Califf, expressing serious concerns about the FDA’s decision to loosen standards governing use of the abortion drug mifepristone and demanding answers regarding the recent changes. […] In addition to Sen. Cruz, the following members of Congress also signed onto the letter: […] Rep. Mike Pompeo (R-Kan.)[.]” [Sen. Cruz, Press Release, 4/26/16]
Cruz Letter Criticized Clinton-Era Approval Process For Mifepristone. According to a press release from Sen. Cruz, “U.S. Sen. Ted Cruz (R-Texas) on Monday joined 74 members of Congress in sending a bicameral letter to Food and Drug Administration (FDA) Commissioner Robert Califf, expressing serious concerns about the FDA’s decision to loosen standards governing use of the abortion drug mifepristone and demanding answers regarding the recent changes. […] Read the letter in its entirety here and below: […] Furthermore, the drug’s original approval process was extremely controversial. At the start of the Clinton Administration, President Clinton issued an Executive Order instructing the FDA to reevaluate the status of the abortion drug. Then-FDA Commissioner Kessler even urged the European patent-holder, Roussel Uclaf, to submit an application for approval of mifepristone. When mainstream drug manufacturers refused to bring this baby-killing drug to the United States, abortion proponents created Danco Laboratories for the sole purpose of distributing the abortion drug in the United States. Finally, the drug was pushed through the approval process in final months of the Clinton administration.” [Sen. Cruz, Press Release, 4/26/16]
Cruz Letter Criticized Mifepristone As “Baby-Killing Drug.” According to a press release from Sen. Cruz, “U.S. Sen. Ted Cruz (R-Texas) on Monday joined 74 members of Congress in sending a bicameral letter to Food and Drug Administration (FDA) Commissioner Robert Califf, expressing serious concerns about the FDA’s decision to loosen standards governing use of the abortion drug mifepristone and demanding answers regarding the recent changes. […] Read the letter in its entirety here and below: […] At the start of the Clinton Administration, President Clinton issued an Executive Order instructing the FDA to reevaluate the status of the abortion drug. Then-FDA Commissioner Kessler even urged the European patent-holder, Roussel Uclaf, to submit an application for approval of mifepristone. When mainstream drug manufacturers refused to bring this baby-killing drug to the United States, abortion proponents created Danco Laboratories for the sole purpose of distributing the abortion drug in the United States.” [Sen. Cruz, Press Release, 4/26/16]
Cruz Letter Called For All Locations Where Mifepristone Was Manufactured. According to a press release from Sen. Cruz, “U.S. Sen. Ted Cruz (R-Texas) on Monday joined 74 members of Congress in sending a bicameral letter to Food and Drug Administration (FDA) Commissioner Robert Califf, expressing serious concerns about the FDA’s decision to loosen standards governing use of the abortion drug mifepristone and demanding answers regarding the recent changes. […] Read the letter in its entirety here and below: […] 6. The locations where mifepristone is manufactured and/or packaged and a list of all FDA safety reviews of these locations in the past 15 years including any site visits conducted by the FDA or at the request of the FDA.” [Sen. Cruz, Press Release, 4/26/16]
Pompeo Said Biden Administration Had Ignored Health Risks Of Abortion Pills In “Haste To Make Abortive Medication Widely Available.” According to Mike Pompeo on Twitter, “Abortion pills introduce real short and long-term risk to young women, but the Biden Administration has ignored these dangers in its haste to make abortive medication widely available.” [Twitter, @MikePompeo, 1/21/23]